Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer

Chemotherapy

Volumn 57, Issue 3, 2011, Pages 236-243

  Chung, Moon Jae ^a   Kim, Yoon Jae ^a   Park, Jeong Youp ^a   Bang, Seungmin ^a   Song, Si Young ^a   Chung, Jae Bock ^a   Park, Seung Woo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Biliary tract cancer; Chemotherapy; Gemcitabine; Irinotecan

Indexed keywords

GEMCITABINE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT CANCER; BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; DYSPEPSIA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEAKNESS; WEIGHT REDUCTION;

ADULT; AGED; ALANINE TRANSAMINASE; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; BILIARY TRACT NEOPLASMS; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL RATE; THROMBOCYTOPENIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79955953781     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000328021     Document Type: Article

References (32)

1. Korea MoHaWRo: Annual report of national cancer information center 2006-2007. http://www.cancer.go.kr/cms/statics/incidence/in-dex.html (accessed July 7, 2010).
2. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51(suppl 6):VI1-VI9. (Pubitemid 35216840)
3. Altaee MY, Johnson PJ, Farrant JM, Williams R: Etiologic and clinical characteristics of peripheral and hilar cholangiocarci-noma. Cancer 1991;68:2051-2055.
4. Khan SA, Thomas HC, Davidson BR, TaylorRobinson SD: Cholangiocarcinoma. Lancet 2005;36:1303-1314. (Pubitemid 41416587)
5. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902. (Pubitemid 46452283)
6. Oh SY, Lee GW, Kim HG, Kim TH, Kim HJ, Kang JH: Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer. Chemotherapy 2008;54:479-484.
7. Hollebecque A, Bouché O, Romano O, Scaglia E, Cattan S, Zerbib P, Heurgue A, Lagarde S, Mariette C, Triboulet JP, Pruvot FR, Hebbar M: Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma. Chemotherapy 2010;56:234-238.
8. Park BK, Kim YJ, Park JY, Bang S, Park SW, Chung JB, Kim KS, Choi JS, Lee WJ, Song SY: Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastroenterol Hepatol 2006;21:999-1003. (Pubitemid 43823285)
9. Ueno H, Kiyosawa K, Kaniwa N: Pharma-cogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer 2007;97:145-151. (Pubitemid 47057479)
10. Bahadori HR, Rocha Lima CM, Green MR, Safa AR: Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999;19:5423-5428. (Pubitemid 30103385)
11. Rocha Lima CM, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Green MR: Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Williston Park) 2002;16(suppl 5):19-24.
12. Schuette W, Nagel S, Juergens S, Bork I, Wollschlaeger B, Schaedlich S, Blankenburg T: Phase II trial of gemcitabine/irinotecan in refractory or relapse dsmall-celllung cancer. Clin Lung Cancer 2005;7:133-137. (Pubitemid 43192130)
13. Rocha-Lima CM, Herndon JE 2nd, Lee ME, Atkins JN, Mauer A, Vokes E, Green MR: Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol 2007;18:331-337. (Pubitemid 46323102)
14. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine mono-therapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-3783. (Pubitemid 41095218)
15. Bhargava P, Jani CR, Savarese DM, O'Donnell JL, Stuart KE, Rocha Lima CM: Gemcitabine and irinotecan in locally advanced or meta-static biliary cancer: preliminary report. Oncology (Williston Park) 2003;17(suppl 8):23-26.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CE-CAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181. (Pubitemid 36962641)
18. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
19. André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008;99:862-867.
20. Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS: Phase II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 2008;53:564-570. (Pubitemid 351170025)
21. Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R: Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2008;26:3702-3708.
22. Lim JY, Jeung HC, Mun HS, Lee DK, Paik YH, Lee SJ, Yoon DS, Cho JY: Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. Anticancer Drugs 2008;19:631-635.
23. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.
24. Djulbegovic B, Frohlich A, Bennett CL: Acting on imperfect evidence: how much regret are we ready to accept? J Clin Oncol 2005;23:6822-6825.
25. van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell-lung cancer cell lines. Br J Cancer 1999;80:981-990. (Pubitemid 29233918)
26. Moufarij MA, Phillips DR, Cellinane C: Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 2003;63:862-869. (Pubitemid 36368993)
27. Cereda S, Passoni P, Reni M, Viganò MG, Aldrighetti L, Nicoletti R, Villa E: The cisplat-in, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer 2010;116:2208-2214.
28. Watkins JF, Mayo MS, Smith HJ, Williamson SK: Gemcitabine, irinotecan and cele-coxib in patients with biliary cancer. Anticancer Drugs 2009;20:294-300.
29. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhöfer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B: Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008;98:309-315. (Pubitemid 351161262)
30. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of erlo-tinib in patients with advanced biliary cancer. J Clin Oncol 2006;24:3069-3074. (Pubitemid 46638942)
31. Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C, Luppi G, Conte P: Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010;102:68-72.
32. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV: Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010;11:48-54.